A highly potent and selective farnesyltransferase inhibitor ABT-100 in preclinical studies.

Gu, Wen-Zhen; Joseph, Ingrid; Wang, Yi-Chun; Frost, David; Sullivan, Gerard M; Wang, Le; Lin, Nan-Horng; Cohen, Jerry; Stoll, Vincent S; Jakob, Clarissa G; Muchmore, Steven W; Harlan, John E; Holzman, Tom; Walten, Karl A; Ladror, Uri S; Anderson, Mark G; Kroeger, Paul; Rodriguez, Luis E; Jarvis, Kenneth P; Ferguson, Debra; Marsh, Kennan; Ng, Shichung; Rosenberg, Saul H; Sham, Hing L; Zhang, Haiying

Gu, Wen-Zhen; Joseph, Ingrid; Wang, Yi-Chun; Frost, David; Sullivan, Gerard M; Wang, Le; Lin, Nan-Horng; Cohen, Jerry; Stoll, Vincent S; Jakob, Clarissa G; Muchmore, Steven W; Harlan, John E; Holzman, Tom; Walten, Karl A; Ladror, Uri S; Anderson, Mark G; Kroeger, Paul; Rodriguez, Luis E; Jarvis, Kenneth P; Ferguson, Debra; Marsh, Kennan; Ng, Shichung; Rosenberg, Saul H; Sham, Hing L; Zhang, Haiying.

Affiliation

Gu WZ; Cancer Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois 60064, USA.

Anticancer Drugs ; 16(10): 1059-69, 2005 Nov.

Article de En | MEDLINE | ID: mdl-16222147

Sujet(s)

Recherche sur Google

Ajouter à My VHL

Imprimer

XML

PubMed Links

Collection: 01-internacional Base de données: MEDLINE Sujet principal: Protéines G ras / Antienzymes / Farnesyltranstransferase / Imidazoles / Tumeurs / Antinéoplasiques Type d'étude: Prognostic_studies Limites: Animals / Humans Langue: En Journal: Anticancer Drugs Sujet du journal: ANTINEOPLASICOS Année: 2005 Type de document: Article Pays d'affiliation: États-Unis d'Amérique Pays de publication: Royaume-Uni

Recherche sur Google

Ajouter à My VHL

Imprimer

XML

PubMed Links